- Trials with a EudraCT protocol (37)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
37 result(s) found for: Pulmonary artery catheter.
Displaying page 2 of 2.
«
Previous
1
2
EudraCT Number: 2015-005211-32 | Sponsor Protocol Number: DS1040-B-U107 | Start Date*: 2017-03-08 | ||||||||||||||||
Sponsor Name:Daiichi Sankyo, Inc. | ||||||||||||||||||
Full Title: A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Single Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of DS-1040b when Added to ... | ||||||||||||||||||
Medical condition: DS-1040b is an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor (TAFIa) intended to be used for the treatment of thrombotic diseases including Pulmonary Embolism (PE) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-014377-40 | Sponsor Protocol Number: Bay 58-2667/14560 | Start Date*: 2010-01-08 | |||||||||||
Sponsor Name:Bayer Healthcare AG | |||||||||||||
Full Title: A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY 58-2667 (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenousl... | |||||||||||||
Medical condition: Acute Decompensated Chronic Congestive Heart Failure (ADHF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) DE (Prematurely Ended) SE (Prematurely Ended) AT (Prematurely Ended) SK (Prematurely Ended) SI (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-006290-25 | Sponsor Protocol Number: 4141 | Start Date*: 2012-05-03 |
Sponsor Name:Copenhagen University Hospital Rigshospitalet, The Heart Center - Department of Thoracic Surgery | ||
Full Title: The Pulmonary Protection Trial (PP-Trial) Pulmonary dysfunction after open heart surgery: Randomized clinical trial with focus on lung-protective interventions | ||
Medical condition: Dysfunction of the lungs after open heart surgery. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-014378-16 | Sponsor Protocol Number: Bay 58-2667/14663 | Start Date*: 2010-01-14 | |||||||||||
Sponsor Name:Bayer Healthcare AG | |||||||||||||
Full Title: A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of Low Dose BAY 58-2667 (25 μg/h, 10 μg/h) Given Intravenously ... | |||||||||||||
Medical condition: Acute Decompensated Chronic Congestive Heart Failure (ADHF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) IE (Prematurely Ended) AT (Prematurely Ended) FR (Prematurely Ended) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000816-96 | Sponsor Protocol Number: P160924 | Start Date*: 2020-04-27 |
Sponsor Name:AP-HP/ DRCI | ||
Full Title: A reduced dose of thrombolytic treatment for patients with intermediate high-risk acute pulmonary embolism | ||
Medical condition: Intermediate high-risk acute pulmonary embolism | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) AT (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) SI (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002022-20 | Sponsor Protocol Number: NL61945.029.17 | Start Date*: 2017-07-27 | |||||||||||
Sponsor Name:VU University Medical Center | |||||||||||||
Full Title: The effect of inspiratory oxygen fraction on the ratio of partial arterial oxygen pressure and inspiratory oxygen fraction (PaO2/FiO2 ratio) in mechanically ventilated patients with and without mil... | |||||||||||||
Medical condition: We investigate the PaO2/FiO2 ratio in patients without and with mild to moderate ARDS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006614-37 | Sponsor Protocol Number: CryoStopPersAF | Start Date*: 2022-05-11 | |||||||||||
Sponsor Name:Region Örebro | |||||||||||||
Full Title: First-line cryoablation for early treatment of Persistent Atrial Fibrillation – a randomized study comparing early trigger isolation using the Cryoballoon versus antiarrhythmic medication. | |||||||||||||
Medical condition: Persistent symptomatic atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023211-34 | Sponsor Protocol Number: | Start Date*: 2011-04-27 | ||||||||||||||||
Sponsor Name:University Hospitals of Leicester NHS Trust | ||||||||||||||||||
Full Title: Randomized Controlled Trial Comparing Intracoronary Administration of Adenosine or Sodium Nitroprusside to Control for Attenuation of Microvascular Obstruction During Primary Percutaneous Coronary ... | ||||||||||||||||||
Medical condition: Acute ST-segment Elevation Myocardial Infarction | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-001387-12 | Sponsor Protocol Number: CCLR325X2202 | Start Date*: 2016-10-11 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, subject and investigator-blind, placebo-controlled study of CLR325 in chronic stable heart failure patients. | |||||||||||||
Medical condition: Stable Heart Failure | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017082-39 | Sponsor Protocol Number: Bay 58-2667 / 14836 | Start Date*: 2010-02-01 | |||||||||||
Sponsor Name:Bayer Healthcare AG | |||||||||||||
Full Title: A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY 58-2667 (50 μg/h, 100 μg/h, 150 μg/h) Given Intravenousl... | |||||||||||||
Medical condition: Acute Decompensated Chronic Congestive Heart Failure (ADHF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) IE (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) FR (Completed) GB (Prematurely Ended) IT (Prematurely Ended) CZ (Prematurely Ended) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003561-16 | Sponsor Protocol Number: TAK-242/01-04-TL-242-011 | Start Date*: 2005-12-21 | |||||||||||
Sponsor Name:Takeda Europe R&D Centre Ltd | |||||||||||||
Full Title: A Pivotal, Multicentre, Multinational, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-242 in Adults with Severe Sepsis | |||||||||||||
Medical condition: Severe sepsis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) FI (Prematurely Ended) AT (Prematurely Ended) CZ (Prematurely Ended) SE (Prematurely Ended) ES (Completed) PT (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011279-56 | Sponsor Protocol Number: IBU/20mg/2009 | Start Date*: 2009-07-31 | |||||||||||
Sponsor Name:Orphan Europe Recordati | |||||||||||||
Full Title: Multicenter open-label pilot study to evaluate the safety, pharmacology and efficacy of a new dose regimen (i.e. 20-10-10 mg/kg) of Pedea (intravenous ibuprofen) in preterm newborn infants of less ... | |||||||||||||
Medical condition: Hemodynamically significant persisting ductus arteriosus in preterm infants of less than 28 weeks of gestational age | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005068-97 | Sponsor Protocol Number: AC-052-414 | Start Date*: Information not available in EudraCT | |||||||||||||||||||||
Sponsor Name:Actelion Pharmaceuticals Ltd. | |||||||||||||||||||||||
Full Title: Effects of combination of bosentan and sildenafil versus sildenafil monotherapy on morbidity and mortality in symptomatic patients with pulmonary arterial hypertension – A multicenter, double - bli... | |||||||||||||||||||||||
Medical condition: Patients to be included must have PAH belonging to WHO Group I, in agreement with the approved indications for sildenafil in PAH by the US FDA: a.Idiopathic (IPAH) b.Familial (FPAH) c.Associated w... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) SE (Completed) DK (Completed) GB (Completed) ES (Completed) PT (Completed) GR (Completed) BE (Completed) CZ (Completed) SK (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-005876-21 | Sponsor Protocol Number: DANOHCA-001 | Start Date*: 2022-07-08 | |||||||||||
Sponsor Name:Department of Cardiology, Copenhagen University Hospital, Rigshospitalet | |||||||||||||
Full Title: The Danish Out-of-Hospital Cardiac Arrest study (DANOHCA) | |||||||||||||
Medical condition: We will investigate the efficacy of four interventions (two pharmaceutical) for reducing mortality and organ damage in patients resuscitated after out-of-hospital cardiac arrest. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016601-42 | Sponsor Protocol Number: F60002 IN 202 G0 | Start Date*: 2010-02-03 | |||||||||||
Sponsor Name:PIERRE FABRE MEDICAMENT | |||||||||||||
Full Title: A phase II multicentric study in adults with acute myelogenous leukaemia (AML) in first complete remission (CR1) using IV BuCy2 in a once daily Bu regimen targeting a narrow therapeutic window prio... | |||||||||||||
Medical condition: Acute myeloid leukaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000885-40 | Sponsor Protocol Number: 04-CL-1904 | Start Date*: 2020-08-27 | |||||||||||
Sponsor Name:Windtree Therapeutics, Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study on the Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock (SEISMiC) | |||||||||||||
Medical condition: Pre-Cardiogenic Shock | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) IT (Completed) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023986-23 | Sponsor Protocol Number: LF-0802 | Start Date*: 2011-05-27 | |||||||||||
Sponsor Name:Agennix Incorporated | |||||||||||||
Full Title: OASIS: A Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Talactoferrin Alfa in Patients with Severe Sepsis | |||||||||||||
Medical condition: Severe Sepsis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) NL (Ongoing) ES (Prematurely Ended) BE (Completed) DK (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
«
Previous
1
2
